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Key Clinical Message
A patient affected by rheumatoid arthritis developed a squamous-cell carcinoma
probably due to abatacept, according to Naranjo algorithm. The case describes
this adverse reaction for the first time and highlights the need for additional
studies to establish the long-term risk profile of abatacept.
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Introduction
Abatacept is a fusion protein composed of the extracellular
domain of Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4)
and the Fc region of the human immunoglobulin G1
(IgG1) that acts as a selective T-cell costimulation modula-
tor [1]. Therapeutic indications of abatacept include
rheumatoid arthritis (RA) not responding to traditional
disease-modifying antirheumatic drugs (DMARDs) and
refractory active polyarticular juvenile idiopathic arthritis
(JIA) [2].
Summary of product characteristics (SPC) [2] for
abatacept reports the possibility of basal-cell carcinoma
and skin papilloma as uncommon events, lymphoma and
malignant lung neoplasm as rare events. We describe the
case of a patient who developed a squamous-cell carci-
noma (SCC) of the tongue after 1 year of treatment with
abatacept for refractory RA. The case was reported by the
University Hospital of Sassari (AOUSS) to the “Sardinian
Regional Center of Pharmacovigilance”, Unit of Clinical
Pharmacology, University Hospital of Cagliari (AOUCA),
as provided by the project entitled “Development of a
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Pharmacovigilance Network in Sardinia”. As biologics are
newer drugs, there is a lack of long-term safety data. This
case report adds to the little information available about
them.
Case Report
A 50-year-old woman with a long history of RA
presented a tongue ulcer after 1 year of therapy with
abatacept 750 mg every 4 weeks intravenously and
leflunomide 20 mg/day. The tongue ulcer was subjected
to biopsy and histopathology revealed “moderately differ-
entiated SCC of the lateral left border of the tongue.” In
view of the possible role of abatacept in the development
of the adverse reaction, therapy with this drug was
discontinued.
The patient was diagnosed with RA at the age of
33 years. Symptoms included stiffness and arthritis of
metacarpophalangeals, proximal interphalangeal joints of
the hand, metatarsal interphalangeals, ankle and left knee
joints. The patients had no comorbidities, apart from a his-
tory of allergy to penicillin, wool, dermatophagoides fari-
nae and pteronyssinus, crustaceans, and peas. The patient
was treated up to 2005 with low doses of methylpredniso-
lone and sulfasalazine (500 mg thrice daily, orally). Ther-
apy with methotrexate IM was started and discontinued
after 2 months for urticarial rush. In December 2005, the
patient started therapy with adalimumab (40 mg twice
weekly), leflunomide (20 mg, orally, one tablet every
2 days), and celecoxib (up to 200 mg twice daily, as
needed). From May 2008, the patient switched to once-
weekly treatment with adalimumab and daily treatment
with leflunomide. In October 2009, therapy with ada-
limumab was suspended due to respiratory difficulty and
urticarial rush following drug injection. The patient started
receiving etanercept (50 mg weekly) but therapy was sus-
pended 3 months later due to insurgence of urticarial reac-
tions and respiratory difficulty. From April 2010 to August
2011, the patient was treated with abatacept 750 mg
monthly in association with leflunomide 20 mg daily
(reduced to 20 mg every 2 days from March 2011), achiev-
ing clinical remission. In September 2011, after histopa-
thology confirmation of SCC of the tongue, therapy with
abatacept was discontinued. From September 2011 to June
2012, the patient was treated with leflunomide 20 mg/day
and methylprednisolone as needed. From June 2012, ther-
apy included methotrexate (10 mg/week, subcutaneously,
augmented to 15 mg/week from December 2012), calcium
folinate 10 mg/week, leflunomide 20 mg/day, risedronate
sodium (75 mg every 2 weeks), calcium carbonate and
cholecalciferol (vitamin D3) 500 mg + 440 UI (2 tablets
daily from December 2011), methylprednisolone, and non-
steroidal anti-inflammatory drugs as needed.
The patient had no personal history of risk factors for
SCC of the tongue: she was not a smoker at the moment
of observation (albeit being an occasional smoker in her
youth, smoking a cigarette every few days) and her alco-
hol intake was restricted to one glass of wine during
meals in rare occasions. The patient had a familial history
of RA (cousin of the mother) and lung cancer (first-
grade cousin, 68 years old).
In September 2011, following the histopathology
report, the patient was admitted to hospital and sub-
jected to left glossectomy, left cervical lymphadenectomy,
and reconstruction of the intraoral defect using a myo-
mucosal flap from the buccinator muscle. Surgical
pathology report showed resection margins were free of
involvement and reactive lymph nodes were metastasis-
free. Thus, cancer was staged as T1N0Mx. At the last
infusion of abatacept, physical examination revealed nor-
mal findings and clinical remission. Laboratory test
results showed normal except for mild neutropenia and
relative lymphocytosis: neutrophils 1.49 9 103/mL (1.8–
8), 23.3% (35–80), and lymphocytes 3.59 9 103/mL (1.5–
4). Six and 10 months after surgery, no clinical, echogra-
phy, or computed tomography (CT) signs of relapse were
observed.
The case was reported to the Italian regulatory author-
ity (report number of Italian spontaneous-reporting data-
base: 157854) and to the manufacturer of the drug.
Discussion
Case report information was collected according to
“Guidelines for submitting adverse event reports for pub-
lication” [3] in order to offer a clearer differential diagno-
sis for the event. Applying Naranjo algorithm [4] and
World Health Organization (WHO) algorithm of Uppsala
Monitoring Centre [5], the score generated suggested that
the adverse reaction was probable due to abatacept and to
leflunomide. Other causes of SCC of the tongue were
considered rather unlikely, as suggested by personal and
familial history of the patient. The adverse reaction had a
reasonable time relationship to abatacept intake and
could be speculated as an adverse reaction arising from
long-term use (type C according to Edwards and Aron-
son, 2000)[6].
On the basis of available evidence, the adverse reaction
described seems to be more probably due to abatacept
than leflunomide, as therapy with leflunomide does not
seem to be associated to insurgence of malignancies,
according to data from large European registers [7]. In
fact, even if an increase in the risk of pancreatic cancer
was hypothesized on the basis of seven cases detected in
the German biologics register (RABBIT), this risk was not
confirmed by a subsequent replication analysis conducted
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on the national biologics registers in the UK and Sweden
[7]. However, interaction between the two drugs cannot
be completely excluded.
To the best of our knowledge, this adverse reaction
during therapy with abatacept has not been previously
reported: although SPC for abatacept [1] does report inci-
dence of malignancies (in particular, basal-cell carcinoma
and skin papilloma as uncommon events; lymphoma and
malignant lung neoplasm as rare events), specific cases of
SCC of the tongue associated to use of this drug have not
been described until now. SPC for abatacept [1] states
that “the potential role of abatacept in the development
of malignancies, including lymphoma, in humans is
unknown.”
A Cochrane review on efficacy and safety of abatacept
in patients with RA [8] outlined the necessity of long-
term studies and postmarketing surveillance to assess
harms and sustained efficacy of abatacept. This necessity
was also confirmed by the overview of Cochrane reviews
on biologics for RA [9]: even though the review did not
show statistically significant difference between patients
receiving abatacept and placebo with regard to safety,
the authors outlined the lack of precise information
about rare side effects, including certain types of cancer.
The recent network meta-analysis and Cochrane over-
view [10] showed that abatacept seemed to be associated
with significantly fewer serious infections and serious
adverse events compared to other biologics. However, a
limitation of this review is the choice of limiting inclu-
sion to RCTs and their open label extensions, whereas
long-term observational studies, including population-
based registries, could provide better estimates of the
long-term safety of biologics. The authors outlined the
urgent need for more research addressing the issue of
rare or long-term adverse effects of biologics. A recent
systematic review and meta-analysis [11] showed no sta-
tistically significant increased risk of malignancy among
RA patients treated with biologic response modifiers
(BRMs) compared with other DMARDs or with placebo
in RCTs with a duration of at least 6 months. However,
additional observational studies are warranted to estab-
lish risk in the longer term.
Conclusions
Based on the case presented, our opinion is that a rela-
tion between therapy with abatacept and onset of the
SCC of the tongue is plausible. Active postmarketing sur-
veillance is essential to a better understanding of the
safety profile of this drug. Even if the limitation of being
a single case report must be taken into account, given the
urgent necessity of collecting more information on the
possible relation between malignancies and abatacept, we
believe this work could be a valid contribution to the
existing literature.
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